In response to the letter (31 January) from Mark Samuels, chief executive of the British Generic Manufacturers Association (BGMA), we want to assure readers that supporting the health system to tackle shortages is a priority for the Medicines and Healthcare Products Regulatory Agency (MHRA) and that we work with many partners, including the BGMA, to do so.
We are taking significant steps to assess applications for generic and established medicines in the shortest time possible. We will always prioritise applications according to public health need.